

DR. DAAN VAN WESSEL (Orcid ID : 0000-0003-0730-0201)

PROF. EMMANUEL GONZALES (Orcid ID : 0000-0002-1546-3193)

PROF. ETIENNE SOKAL (Orcid ID : 0000-0001-5597-4708)

MISS STEFFEN HARTLEIF (Orcid ID : 0000-0002-2608-5087)

PROF. HUEY-LING CHEN (Orcid ID : 0000-0002-4285-5686)

Article type : Original

Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency

Daan B.E. van Wessel,¹ Richard J. Thompson,² Emmanuel Gonzales,^{3,4} Irena Jankowska,^{4,5} Benjamin L. Shneider,^{6,7} Etienne Sokal,^{4,8} Tassos Grammatikopoulos,² Agustina Kadaristiana,² Emmanuel Jacquemin,^{3,9} Anne Spraul,^{3b,9} Patryk Lipiński,^{4,5} Piotr Czubkowski,^{4,5} Nathalie Rock,⁸ Mohammad Shagrani,^{10,10b} Dieter Broering,¹⁰ Talal Algoufi,¹⁰ Nejat Mazhar,¹⁰ Emanuele Nicastro,¹¹ Deirdre Kelly,^{4,12} Gabriella Nebbia,¹³ Henrik Arnell,^{4,14} Björn Fischler,^{4,14} Jan B.F. Hulscher,^{4,15} Daniele Serranti,¹⁶ Cigdem Arikian,¹⁷ Dominique Debray,¹⁸ Florence Lacaille,¹⁸ Cristina Goncalves,^{4,19} Loreto Hierro,^{4,20} Gema Muñoz Bartolo,^{4,20} Yael Mozer-Glassberg,²¹ Amer Azaz,²² Jernej Breclj,²³ Antal Dezsőfi,²⁴ Pier Luigi Calvo,²⁵ Dorothee Krebs-Schmitt,²⁶ Steffen Hartleif,^{4,27} Wendy L. van der Woerd,²⁸ Jian-She Wang,²⁹ Li-ting Li,²⁹ Özlem Durmaz,³⁰ Nanda Kerkar,³¹ Marianne Hørby Jørgensen,^{4,32} Ryan Fischer,³³ Carolina Jimenez-Rivera,³⁴ Seema Alam,³⁵ Mara Cananzi,^{4,36} Noémie Laverdure,^{4,37} Cristina Targa Ferreira,³⁸ Felipe Ordóñez,³⁹ Heng Wang,⁴⁰ Valerie Sency,⁴⁰ Kyung Mo Kim,⁴¹ Huey-Ling Chen,⁴² Elisa Carvalho,⁴³ Alexandre Fabre,⁴⁴ Jesus Quintero Bernabeu,^{4,45} Estella M. Alonso,^{7,46} Ronald J. Sokol,^{7,47} Frederick J. Suchy,^{7,48} Kathleen M. Loomes,^{7,49} Patrick J. McKiernan,^{7,50} Philip Rosenthal,^{7,51} Yumirle Turmelle,^{7,52} Girish S. Rao,^{7,53} Simon Horslen,^{7,54} Binita M. Kamath,^{7,55} Maria Rogalidou,⁵⁶ Wikrom W. Karnsakul,⁵⁷ Bettina Hansen,^{58,58b} and Henkjan J. Verkade^{1,4}

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/HEP.31787](#)

This article is protected by copyright. All rights reserved

From the ¹Pediatric Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ²Institute of Liver Studies, King's College Hospital, Denmark Hill, London, United Kingdom; ³Pediatric Hepatology & Pediatric Liver Transplant Department, Centre de Référence de l'Atrésie des Voies Biliaires et des Cholestases Génétiques (AVB-CG), Filière de Santé des Maladies Rares du Foie de l'enfant et de l'adulte (FILFOIE), European Reference Network RARE-LIVER, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Saclay, CHU Bicêtre, Le Kremlin-Bicêtre, Paris, France; ^{3b}Biochemistry Unit, Centre de Référence de l'Atrésie des Voies Biliaires et des Cholestases Génétiques (AVB-CG), Filière de Santé des Maladies Rares du Foie de l'enfant et de l'adulte (FILFOIE), European Reference Network RARE-LIVER, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Paris-Saclay, CHU Bicêtre, Le Kremlin-Bicêtre, Paris, France; ⁴European Reference Network on Hepatological Diseases (ERN RARE-LIVER); ⁵Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland; ⁶Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine, Houston, TX; ⁷Childhood Liver Disease Research Network (ChiLDReN); ⁸Université Catholique de Louvain, Cliniques St Luc, Brussels, Belgium; ⁹Université Paris-Saclay, INSERM, UMR-S 1193, Hepatinov, Orsay, France; ¹⁰Department of Liver & SB Transplant & Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, ^{10b}Alfaisal University, College of Medicine, Riyadh, Saudi Arabia; ¹¹Pediatric Hepatology, Gastroenterology and Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy; ¹²Liver Unit, Birmingham Women's and Children's Hospital and University of Birmingham, Birmingham, United Kingdom; ¹³Servizio Di Epatologia e Nutrizione Pediatrica, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; ¹⁴Pediatric Digestive Diseases, Astrid Lindgren Children's Hospital, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden; ¹⁵Pediatric Surgery, University Medical Center Groningen, Groningen, the Netherlands; ¹⁶Pediatric and Liver Unit, Meyer Children's University Hospital of Florence, Florence, Italy; ¹⁷Koc University School of Medicine, Pediatric GI and Hepatology Liver Transplantation Center, Kuttam System in Liver Medicine, Istanbul, Turkey; ¹⁸Pediatric Hepatology unit, Reference center for Biliary atresia and genetic cholestatic diseases (AVB-CG), Filière de Santé des Maladies Rares du Foie de l'enfant et de l'adulte (FILFOIE), European Reference Network RARE-LIVER, APHP-Neckler Enfants malades university hospital, Faculté de Médecine Paris-Centre, Paris, France; ¹⁹Coimbra University

Hospital Center, Coimbra, Portugal; ²⁰Pediatric Liver Service, La Paz University Hospital, Madrid, Spain; ²¹Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel; ²²Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; ²³Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital Ljubljana, and Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ²⁴1st Department of Pediatrics, Semmelweis University, Budapest, Hungary; ²⁵Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital, Azienda Ospedaliera Città Della Salute e Della Scienza University Hospital, Torino, Italy; ²⁶Klinik Für Kinder-Und Jugendmedizin, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; ²⁷University Children's Hospital Tübingen, Tübingen, Germany; ²⁸Wilhelmina Children's Hospital, University Medical Center Utrecht, Pediatric Gastroenterology, Hepatology and Nutrition, Utrecht, the Netherlands; ²⁹Children's Hospital of Fudan University, Shanghai, China; ³⁰Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey; ³¹Pediatric Gastroenterology, Hepatology and Nutrition, University of Rochester Medical Center, Rochester, NY; ³²Pediatric and adolescent department Rigshospitalet Copenhagen University Hospital, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ³³Children's Mercy Hospital, Section of Hepatology and Transplant Medicine, Kansas City, MO; ³⁴Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, Canada; ³⁵Institute of Liver and Biliary Sciences, Pediatric Hepatology, New Delhi, India; ³⁶University Hospital of Padova, Pediatric Gastroenterology and Hepatology, Padova, Italy; ³⁷Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de gastroentérologie, hépatologie et nutrition pédiatriques, Lyon, France; ³⁸Hospital da Criança Santo Antônio, Pediatric Gastroenterology, Porto Alegre, Brazil; ³⁹Fundación Cardioinfantil Instituto de Cardiología, Pediatric Gastroenterology and Hepatology, Bogotá, Colombia; ⁴⁰DDC Clinic Center for Special Needs Children, Middlefield, OH; ⁴¹Asan Medical Center Children's Hospital, Department of Pediatrics, Seoul, South Korea; ⁴²National Taiwan University Children's Hospital, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Taipei, Taiwan; ⁴³Brasília Children's Hospital, Pediatric Gastroenterology and Hepatology, Brasilia, Brazil; ⁴⁴Aix Marseille University, INSERM, MMG, Marseille, France, and APHM, Timone Enfant, service de pédiatrie multidisciplinaire, Marseille, France; ⁴⁵Pediatric Hepatology and Liver Transplant Unit, Barcelona, Spain; ⁴⁶Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital, Chicago, IL; ⁴⁷Children's Hospital Colorado, Section of

Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO; ⁴⁸Mount Sinai Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York City, NY; ⁴⁹Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA; ⁵⁰Department of Pediatric Gastroenterology and Hepatology, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA; ⁵¹Department of Pediatrics and Surgery, UCSF Benioff Children's Hospital, UCSF School of Medicine, San Francisco, CA; ⁵²Section of Hepatology, Department of Pediatrics, St Louis Children's Hospital, Washington University School of Medicine, St Louis, MO; ⁵³Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN; ⁵⁴Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA; ⁵⁵The Hospital for Sick Children and the University of Toronto, Toronto, Canada; ⁵⁶Division of Pediatric Gastroenterology & Hepatology, 1st Pediatrics Department, University of Athens, Agia Sofia Children's Hospital, Athens, Greece; ⁵⁷Division of Pediatric Gastroenterology, Nutrition, and Hepatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; ⁵⁸Toronto Center for Liver Disease, University Health Network, Canada, ^{58b}IHPME, University of Toronto, Canada, Natural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium.

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Henkjan J. Verkade M.D., Ph.D.

Pediatric Gastroenterology & Hepatology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen

PO Box 30.001

9700 RB Groningen, the Netherlands

E-mail: h.j.verkade@umcg.nl

Tel.: +31(0)50 361 61 61

Financial Support: This study was supported by M.D./Ph.D. scholarship from the University of Groningen, Groningen, the Netherlands; European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Networking Grant 2019; ChilDReN National Institutes of Health grants: Ann & Robert H. Lurie Children's Hospital, Chicago, IL (U01DK062436 to E.A.); University of Colorado, Denver, CO (U01DK62453, UL1 TR002535 both to R.S.); Baylor

College of Medicine, Houston, TX (U01DK103149 to B.S.); Children's Hospital of Philadelphia, Philadelphia, PA (U01DK062481, UL1TR000003 both to K.L.); Children's Hospital of Pittsburgh, Pittsburgh, PA (U01DK062466 to P.M.); St Louis Children's Hospital, St Louis, MO (U01DK062500, UL1TR001872 both to Y.T.); Riley Hospital for Children, Indianapolis, IN (U01DK084536 to G.R.); Seattle Children's Hospital, Seattle, WA (DK084575 to S.H.); and unrestricted research grants from Albireo and Mirum Pharmaceuticals.

Abbreviations: ABCB11, adenosine triphosphate (ATP)-binding cassette, subfamily B, member 11; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATP, adenosine triphosphate; ATP8B1, ATPase phospholipid transporting 8B1; AUC, area under the curve; BRIC, benign recurrent intrahepatic cholestasis; BSEP, bile salt export pump; ChiLDReN, Childhood Liver Disease Research Network; CI, confidence interval; EHC, enterohepatic circulation; FIC1, familial intrahepatic cholestasis type 1; GGT, gamma-glutamyltranspeptidase; HCC, hepatocellular carcinoma; IE, ileal exclusion; LT, liver transplantation; NAPPED, NATural course and Prognosis of PFIC and Effect of biliary Diversion; NLS, native liver survival; PEBD, partial external biliary diversion; PFIC, progressive familial intrahepatic cholestasis; PLT, platelet count; PPTM, predicted protein truncating mutation; REDCap, Research Electronic Data Capture; ROC, receiver operating characteristic; sBA, serum bile acid; SBD, surgical biliary diversion; TSB, total serum bilirubin; UDCA, ursodeoxycholic acid.

Potential conflict of interest: Daan B.E. van Wessel received an M.D./Ph.D. scholarship from the University of Groningen; Richard J. Thompson has consulted for Shire, Albireo, Mirum Pharmaceuticals, Horizon Pharmaceuticals, Sana Biotechnology, Generation Bio, Retrophin, Evox Therapeutics, and Qing Bile Therapeutics; Emmanuel M. Gonzales has consulted for Albireo, CTRS, Mirum Pharmaceuticals, and Vivet Therapeutics; Etienne M. Sokal is the founder, board director, and chairman of the Scientific & Medical Advisory Board of Promethera Biosciences and consultant for Johnson & Johnson; Emmanuel Jacquemin has consulted for CTRS and Vivet Therapeutics; Deirdre Kelly has received grant support for clinical trials and served as a consultant and advisory board member for Intercept, Mirum Pharmaceuticals, and Albireo; Henrik Arnell has consulted for Albireo and Mirum Pharmaceuticals; Björn Fischler attended one advisory board meeting with Albireo in 2016; Dominique Debray has consulted for Alexion Pharmaceuticals;

Binita Kamath has consulted for Mirum Pharmaceuticals, Shire, and DCI; Jian-She Wang has consulted for Albireo, Intercept, and Mirum Pharmaceuticals; Nanda Kerkar has served on the High Tide Advisory Panel; Jesus Quintero Bernabeu has consulted for Alexion Pharmaceuticals; Ronald J. Sokol has consulted for Albireo, Mirum Pharmaceuticals, and Retrophin; Kathleen M. Loomes has consulted for Albireo and Mirum Pharmaceuticals; Patrick J. McKiernan has consulted for Albireo; Philip Rosenthal has provided research support for Albireo, Mirum Pharmaceuticals, Merck, Gilead, AbbVie, Arrowhead, and Retrophin and consulted for Gilead, AbbVie, Albireo, Mirum Pharmaceuticals, Audentes, Dicerna, and Retrophin; Wikrom W. Karnsakul has consulted for Albireo; Bettina Hansen has consulted for Mirum Pharmaceuticals, Albireo, Chemomab, Calliditas, Intercept, and CymaBay and received unrestricted grants from CymaBay, Intercept, Mirum Pharmaceuticals, and Albireo; Henkjan J. Verkade has consulted for Danone Nutricia Research, Ausnutria B.V., Albireo AB, GMP-Orphan, Mirum Pharmaceuticals, Intercept, and Vivet Therapeutics.

Keywords: FIC1 deficiency; PFIC1; ATP8B1; surgical biliary diversion; serum bile acids.

ABSTRACT

Mutations in *ATP8B1* can lead to familial intrahepatic cholestasis type 1 (FIC1) deficiency, or progressive familial intrahepatic cholestasis type 1 (PFIC1). The rarity of FIC1 deficiency has largely prevented a detailed analysis of its natural history, effects of predicted protein truncating mutations (PPTMs), and possible associations of serum bile acid (sBA) concentrations and surgical biliary diversion (SBD) with long-term outcome. We aimed to provide novel insights by using the largest genetically defined cohort of FIC1 deficiency patients to date. This multicenter, combined retrospective and prospective study included 130 patients with compound heterozygous or homozygous predicted pathogenic *ATP8B1* variants. Patients were categorized according to the number of PPTMs (i.e., splice site, frameshift due to deletion or insertion, nonsense, duplication); FIC1-A (n=67; no PPTM), FIC1-B (n=29; one PPTM) or FIC1-C (n=34; two PPTMs). Survival analysis showed an overall native liver survival (NLS) of 44% at age 18y. NLS was comparable between FIC1-A, FIC1-B, and FIC1-C (%NLS at age 10y: 67%, 41%, and 59%, respectively; $P=0.12$), despite FIC1-C undergoing SBD less often (%SBD at age 10y: 65%, 57%, and 45%, respectively; $P=0.03$). sBAs at presentation were negatively associated with NLS (NLS at age 10y; sBAs <194 $\mu\text{mol/L}$: 49% versus sBAs ≥ 194 $\mu\text{mol/L}$: 15%; $P=0.03$). SBD decreased sBAs (230 [125-282] to 74 [11-177] $\mu\text{mol/L}$; $P=0.005$). SBD (HR 0.55, 95% CI 0.28-1.03, $P=0.06$) and post-SBD sBA concentrations <65 $\mu\text{mol/L}$ ($P=0.05$) tended to be associated with improved NLS. **Conclusion:** Less than half of FIC1 deficiency patients reach adulthood with native liver. The number of PPTMs did not associate with the natural history or prognosis of FIC1 deficiency. sBA concentrations at initial presentation and after SBD provide limited prognostic information on long-term NLS.

Introduction

Familial intrahepatic cholestasis type 1 (FIC1) deficiency, or progressive familial intrahepatic cholestasis type 1 (PFIC), results from mutations in the adenosine triphosphate (ATP)ase phospholipid transporting 8B1 (*ATP8B1*) gene.⁽¹⁻⁴⁾ FIC1 is a member of ATP-dependent phospholipid flippases, which maintain a phospholipid asymmetry across phospholipid bilayers, such as the canalicular membrane.⁽⁵⁾ Mutations in *ATP8B1* are thought to disrupt the physiological membrane structure, leading to impaired biliary bile salt excretion,⁽⁶⁾ yet the exact mechanism by which this occurs remains elusive. Indirect inhibition of other canalicular transporters (e.g., the

bile salt export pump [BSEP]) by increased vulnerability to canalicular bile acids as well as down-regulation of the farnesoid X receptor are among the proposed responsible mechanisms.^(5,7-12) Patients with FIC1 deficiency typically present with cholestasis and pruritus in early childhood, often progressing into end-stage liver disease (ESLD).^(13,14) FIC1 is expressed in tissues other than liver. Deficiency of FIC1 therefore results in a range of extrahepatic manifestations, such as diarrhea, pancreatitis, and hearing loss.⁽¹⁴⁻²²⁾ FIC1 deficiency has been largely refractory to medical treatment, yet surgical biliary diversion (SBD) procedures may decrease pruritus and slow the development of liver fibrosis.^(13,18,23-26) Patients in whom cholestasis does not (sufficiently) respond to medical treatment or SBD are potential candidates for liver transplantation (LT). Although LT may be indicated for severe cholestasis and/or ESLD, it cannot be considered as a total cure of the underlying genetic disease due to the extrahepatic expression of FIC1 and therefore the presence or even development of extrahepatic symptoms after LT. SBD can still be indicated after LT to prevent or treat graft steatofibrosis and secondary intestinal lymphangiectasia.⁽²⁷⁾

FIC1 deficiency is a rare disease, and therefore its natural history and genotype-phenotype relationships have not been characterized in large, genetically defined cohorts. We therefore aimed to provide detailed insights into the natural history and genotype-phenotype associations and to assess the effect of SBD on native liver survival (NLS). Since 2017, we have been collecting patient data in a global consortium: NAPPED (NATural course and Prognosis of PFIC and Effect of biliary Diversion). NAPPED has become a large, international initiative that aims to characterize the natural course of disease in severe FIC1 (and severe BSEP deficiency) to assess the effect of genetic, clinical, and therapeutic parameters on long-term outcome.

Material and Methods

Data collection, patient selection, and genetic categorization

Since its start in 2017, NAPPED has collected retrospective data on patients with FIC1 deficiency (and severe BSEP deficiency caused by mutations in ATP-binding cassette, subfamily B, member 11 [*ABCB11*], data which have recently been published⁽²⁸⁾). The Childhood Liver Disease Research Network (ChiLDReN) collected data prospectively. NAPPED currently comprises 68 referral centers from Europe, North America, South America, Africa, Asia, and Australia. Data for the present study were collected conforming to the guidelines of the 1975 Declaration of Helsinki. Data collection and management used a prespecified case-record form and was captured using Research Electronic Data Capture (REDCap).⁽²⁹⁾ Demographic, clinical, and outcome data were collected by investigators within each center, who identified all consecutive patients who had ever been under pediatric care (age 0-18 years) since 1981. From ChiLDReN, all cases of FIC1 deficiency enrolled in the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) since 2007 were included. Data reported in the present manuscript were exported from REDCap May 1, 2020. Patients with pathological compound heterozygous or homozygous *ATP8B1* mutations were selected from the database. The pathogenicity of mutations was based on existing literature and databases, including in vitro studies.^(4,30-32) Patients without available genetic reports or with mutations of no identifiable pathological significance were excluded. Included patients were further categorized based on their genotype vis-à-vis predicted protein truncating mutations (PPTMs) (i.e., splice site, frameshift due to deletion or insertion, nonsense, duplication); FIC1-A patients harbored no PPTMs, FIC1-B patients harbored one PPTM, and FIC1-C patients harbored two PPTMs. We further categorized patients with homozygous mutations based on the location of their mutations in the FIC1 protein. Biochemistry at presentation in the tertiary center, as well as prior to SBD and between 2 months and 1 year after SBD, were analyzed. If such information was available from the medical file, pruritus was scored as “absent,” “mild to moderate,” or “severe” at the discretion of the participating center, which, for statistical purposes, was dichotomized later into “absent” or “present.” Effect of SBD on pruritus was noted as “no improvement in pruritus,” “transient (partial or complete) relief of pruritus,” or “sustained (partial or complete) relief of pruritus.” Analyses were performed with regard to important clinical events in the form of SBD, LT, or death. Extrahepatic features have not (yet) been documented in the NAPPED REDCap database and are hence not analyzed in the present paper.

Statistical evaluation

Continuous variables are expressed as medians and interquartile range (IQR). Non-normally distributed data were analyzed using the appropriate nonparametric methods, including Mann-Whitney and Kruskal-Wallis tests. Differences between categorical variables were assessed using χ^2 , McNemar, or Mantel's test for trend, as appropriate. Unadjusted differences in disease-free survival (DFS) and NLS between patient subgroups were assessed by using Kaplan-Meier estimates and compared using the log-rank test. The following factors were included in the analyses: sex, birth year, age at first visit at referral center, use of medical therapy prior to first visit (e.g., ursodeoxycholic acid [UDCA], rifampicin, phenobarbital, cholestyramine, antihistamines), occurrence of hepatocellular carcinoma (HCC), serum bile acids (sBAs) (not standardized for fasting/post-prandial state), total serum bilirubin (TSB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), and platelet count (PLT). Units of sBAs ($\mu\text{mol/L}$), TSB ($\mu\text{mol/L}$), AST (IU/L), ALT (IU/L), and GGT (IU/L) were converted, if needed. Time-dependent Cox regression was applied for studying the association between SBD and NLS in all patients (hazard ratios [HRs] and 95% confidence intervals [CIs]). Sex, genotype, birth year, and SBD as a time-dependent factor for NLS were included in the multivariate model. The model was extended with additional factors one by one to assess the association with the endpoint. Because data were collected from multiple sites, sensitivity analyses (i.e., stepwise exclusion of centers, as well as stepwise exclusion of geographic regions from the analysis) were performed to control for the heterogeneity between sites. A clock-reset approach was used to visualize the association of SBD with NLS. All patients start without SBD. Then, patients who underwent SBD during follow-up are censored at the age of SBD and restart with a new risk in the SBD curve. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-off for biochemistry at presentation and post-SBD biochemistry in relation to predicting NLS after these points in time. The number of patients for whom data were present for each variable is indicated. Imputation of missing data was not attempted.

A 2-sided P value <0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics for Windows 23.0 (Armonk, NY). Figures were constructed using IBM SPSS Statistics for Windows 23.0 (Armonk, NY) and GraphPad Prism 7.02 for Windows (GraphPad Software, La Jolla, CA).

Results

Baseline data

The present study included 130 patients with compound heterozygous or homozygous pathological *ATP8B1* mutations and a low-GGT cholestasis phenotype (Fig. 1; data exported from REDCap May 1, 2020). Among the patients, 15 initially presented with a benign recurrent intrahepatic cholestasis (BRIC) phenotype that later evolved into a severe FIC1 deficiency (PFIC1) phenotype. Six patients fulfilling the genetic inclusion criteria were excluded because they persistently presented a BRIC phenotype and not a severe FIC1 deficiency (PFIC1) phenotype. Of the 130 patients, 48 (37%) had been described in the literature; 520 patients were excluded because mutations did not meet our inclusion criteria, and 103 were excluded because genetic reports were not available (Fig. 1). We identified two cohorts with a homozygous mutation, that is, c.923G>T; p.Gly308Val (n = 18) or c.1660G>A; p.Asp554Asn mutation (n = 8). The included patients were followed in centers from Europe (n = 58), North America (n = 37), and Asia (n = 35). Supporting Table S1 provides the observed mutations per included patient, and Supporting Fig. S1 shows the locations of all observed mutations in the FIC1 protein.

There were 71 (55%) males in this cohort of 130 patients with FIC1 deficiency (Table 1). The median birth year was 2007 (1999-2012). Age at first presentation to the tertiary center was 0.6 (0.3-2.2) years, illustrating the early onset of disease. Before or at presentation, 40% of the patients had used or were receiving UDCA. As expected, at presentation patients had elevated total sBAs and TSB with elevated aminotransferases. During follow-up of a median of 4.2 (2.2-9.8) years, 62 of 130 patients (48%) had undergone an SBD and 38 of 130 patients (29%) had undergone LT (Supporting Table S2). HCC was not diagnosed in any of the patients, either before transplantation or in explant. A total of 8 patients (6%) died prior to LT, of which 3 underwent SBD during follow-up. Deaths were related to liver disease in 7 patients (age at death 5.0 years [range, 3.2-10.7]) and unrelated to liver disease in 1 patient (death due to head trauma at age 13.2 years). Survival analysis showed that at 18 years of age, 44% of patients were alive with their native liver (Fig. 2). During adulthood (i.e., ≥ 18 years of age), 2 patients underwent LT (ages 20.0 and 20.2 years, indications for LT; pruritus [n = 1], unknown [n = 1]).

Associations between genotype category and characteristics at presentation

Table 1 depicts patient characteristics and biochemistry at presentation to the tertiary referral center for all FIC1 patients according to the genotype categories (FIC1-A: n = 67; FIC1-B: n = 29; FIC1-C: n = 34). Patients with an FIC1-C genotype presented to the referral center at 0.4 years (range, 0.2-0.7), that is, 0.4 and 0.5 years earlier compared to FIC1-A and FIC1-B, respectively ($P = 0.01$). At presentation, levels of sBAs, aminotransferases, and GGT were comparable among the three genotype groups. FIC1-B patients presented the highest TSB levels (FIC1-A 113 [61-193], FIC1-B 212 [123-373], and FIC1-C 125 [65-173] $\mu\text{mol/L}$; $P = 0.02$). FIC1-C patients presented with higher PLTs (FIC1-A 365 [241-538], FIC1-B 399 [288-484], and FIC1-C 530 [394-625] $10^9/\text{L}$; $P = 0.02$). Half of the patients with an FIC1-A genotype had used or were using UDCA (50%) prior to or at presentation, which was a larger proportion of patients than in the FIC1-B (39%) or FIC1-C (26%) genotypes ($P = 0.01$). The difference in use of UDCA did not seem result in markedly improved biochemistry in comparison to the other patient groups (Table 1). In FIC1-A patients, significant differences in biochemistry at presentation were not observed between patients who had used or were using UDCA and those who never used UDCA. A similar analysis could not reliably be performed for FIC1-B and FIC1-C due to lower numbers.

Associations between baseline characteristics and SBD or NLS

Figure 2 shows that by the age of 18 years, 74% of the patients alive with their native liver had undergone SBD. A lower percentage of patients with an FIC1-C genotype underwent SBD during follow-up (% SBD at 10 years of age: FIC1-A 65%, FIC1-B 57%, FIC1-C 45%; $P = 0.03$; Fig. 3). NLS was comparable between the three genotype groups (% NLS at 10 years of age: FIC1-A 67%, FIC1-B 41%, FIC1-C 59%; $P = 0.15$; Fig. 3). In patients undergoing SBD during follow-up, NLS was comparable (% NLS at 10 years of age: FIC1-A 81%, FIC1-B 67%, FIC1-C 77%; $P = 0.19$; Supporting Fig. S2), as well as in patients not undergoing SBD during follow-up (% NLS at 10 years of age: FIC1-A 39%, FIC1-B 23%, FIC1-C 35%; $P = 0.57$; Supporting Fig. S2). It should be noted that the proportions of patients alive with native liver at the age of 10 years were lower in patients without SBD than in patients who had undergone an SBD during follow-up (Supporting Fig. S2).

During follow-up, relatively more females than males tended to undergo SBD during follow-up (% SBD at 10 years of age: 67% versus 53% in males; $P = 0.06$; Supporting Fig. S3). The NLS of females was comparable to that of males (% NLS at 10 years of age: 67% versus 49%,

respectively; $P = 0.31$; Supporting Fig. S3), as was NLS in females and males not undergoing SBD during follow-up (% NLS at 10 years of age: 39% versus 30%, respectively; $P = 0.84$; Supporting Fig. S4).

We performed ROC analyses for baseline biochemistry in relation to long-term outcome (i.e., NLS). The areas under the curve (AUCs) were highest for sBAs and TSB: 0.71 (0.51-0.92) and 0.62 (0.40-0.83), respectively. Optimal cut-offs for prediction of NLS after first presentation were 194 $\mu\text{mol/L}$ (sensitivity 85%, specificity 72%) for sBAs and 72 $\mu\text{mol/L}$ (sensitivity 69%, specificity 50%) for TSB. These cut-offs were used in subsequent Kaplan-Meier analyses in which the time of presentation at the tertiary referral center was used as time point 0 because the biochemical parameters were recorded at that particular point in time. Patients with an sBA level $<194 \mu\text{mol/L}$ or TSB level $<72 \mu\text{mol/L}$ at presentation had a higher NLS compared to patients with levels above these thresholds: NLS at 15 years after presentation was 49% in patients with sBAs $<194 \mu\text{mol/L}$ and 15% in patients with sBAs $\geq 194 \mu\text{mol/L}$ ($P = 0.03$). NLS at 15 years after presentation was 47% in patients with a TSB $<72 \mu\text{mol/L}$ and 34% in patients with a TSB $\geq 72 \mu\text{mol/L}$ ($P = 0.07$). The long-term outcome, compatible with the association between initial sBAs and outcome, could not be attributed to SBD or to either of the two subgroups (i.e., patients with and without a TSB $<72 \mu\text{mol/L}$ or $\geq 72 \mu\text{mol/L}$ at presentation); there were no significant differences observed in the proportion of patients undergoing SBD over time in these two groups (P values 0.53 and 0.76, respectively). The proportion of patients undergoing SBD during follow-up in patients with sBA levels $<194 \mu\text{mol/L}$ or $\geq 194 \mu\text{mol/L}$ at presentation was comparable; the majority of patients (i.e., 78% and 90%, respectively) underwent SBD before the age of 2.5 years ($P = 0.27$). The distribution of genotype categories was comparable between the two groups (i.e., patients with sBA levels $<194 \mu\text{mol/L}$ or $\geq 194 \mu\text{mol/L}$; $P = 0.17$).

SBD: baseline data

A total of 62 patients underwent an SBD during follow-up, at a median age of 5.9 years (Fig. 2). Based on the limited information available ($n = 22$), it seemed that the main indication for SBD had been pruritus (21/22 [95%]). Of the 62 patients who underwent SBD, 49 underwent partial external biliary diversion (PEBD) (79%), 6 underwent gallbladder-colic diversion (CLD) (10%), 4 underwent ileal exclusion (IE) (5%), 1 underwent total biliary diversion (TBD) (2%), 1 underwent cholecystojejunostomy (2%), and 1 underwent an unknown procedure (2%) (Supporting Table

S2). The estimated proportion of patients alive with native liver with an SBD at the ages of 5, 10, 15, and 18 years of age was 46%, 58%, 65%, and 74%, respectively (Fig. 2). Two patients underwent SBD during adulthood (at ages 18.8 and 20.0 years). Median follow-up after SBD was 5.3 years (derived from Kaplan-Meier curve). The initial diversion was converted to TBD in 3 patients—2 within 1 month after initial SBD and 1 within 1.6 years after initial SBD. None of the initial diversions were surgically closed. LT was performed in a total of 15 of 62 patients (24%) who first underwent SBD (missing data in 1 patient). These patients underwent LT 2.5 (0.7-6.2) years after initial SBD. Paired pruritus data, pre- and post-SBD, were available in 29 patients. Prior to SBD, pruritus had been present in 28 of 29 patients (97%). Post-SBD (i.e., at least 2 months and maximum 1 year after SBD), pruritus was present in 23 of 29 patients (79%) ($P = 0.13$). Retrospective analysis on pruritus data should be interpreted with caution. Nevertheless, some could be derived from the patient files and could provide information of some relevance. In those patients for whom long-term pruritus data were available ($n = 23$), half seemed to (partially) benefit from SBD: In 11 of 23 patients (48%), no improvement of pruritus was reported, whereas 6 of 23 patients (26%) had transient relief and 6 of 23 patients (26%) had sustained (partial or complete) relief of pruritus. A sustained partial or complete relief of pruritus was observed most often in FIC1-C ($n = 4/8$ [50%]), compared to FIC1-A ($n = 1/9$ [11%]) and FIC1-B ($n = 1/6$ [17%]) ($P = 0.03$).

Paired biochemistry data, pre- and post-SBD, were analyzed. We noted a decrease in sBAs (230 [125-282] to 74 [11-177] $\mu\text{mol/L}$; median 49% decrease; $P = 0.005$; Fig. 4). There were no statistically significant differences in the post-SBD sBA levels between FIC1-A (81 [7-191] $\mu\text{mol/L}$), FIC1-B (74 [12-296] $\mu\text{mol/L}$), and FIC1-C (44 [4-136] $\mu\text{mol/L}$) patients ($P = 0.63$) or in TSB, ALT, or AST (P values TSB: 0.89, ALT: 0.46; and AST: 0.42), respectively. Although numbers were small, the post-SBD sBA levels associated with post-SBD presence of pruritus: patients with a post-SBD sBA <65 $\mu\text{mol/L}$ were less likely to experience pruritus ($n = 7/11$ [63%]) compared to patients with a post-SBD sBA ≥ 65 $\mu\text{mol/L}$ ($n = 9/9$ [100%]) ($P = 0.04$).

Association between SBD and NLS

Time-dependent Cox regression analysis (corrected for sex, genotype, and birth year) showed that SBD tended to be associated with NLS (overall HR, 0.55; 95% CI, 0.28-1.03; $P = 0.06$; Fig. 5). However, the association between SBD and NLS was not similar across the three subgroups: An

FIC1-B genotype was associated with a significantly lower NLS (HR, 2.13; 95% CI, 1.09-4.16; $P = 0.03$). We analyzed but could not detect a center bias to underlie this difference. We analyzed proportional hazards and observed that after 7 years of age the proportional hazards seemed higher in FIC1-B compared to FIC1-A and FIC1-C (log minus log plot; Supporting Fig. S5). This led us to use the landmark method (within the time-dependent Cox regression, as stated above) to scrutinize if indeed an FIC1-B genotype was associated with lower NLS, either before 7 years of age or after 7 years of age. The NLS did not significantly differ between the three genotypes of either age. However, in the latter period of time, a relatively high HR was observed in FIC1-B (HR, 2.92; 95% CI, 0.77-11.12; $P = 0.11$; 12 patients in analysis). To test the robustness of the overall regression model, sensitivity analyses were performed; we stratified for geographical region and caseload of the respective centers. HRs remained comparable when stratifying for geographic region (range, 0.52-0.84). Excluding centers one by one yielded comparable results (range, 0.40-0.79; analyses performed for centers contributing more than 5 patients to the present cohort).

Follow-up after diversion

The proportion of patients alive with native liver 10 years after SBD was 70% in FIC1-A, 37% in FIC1-B, and 66% in FIC1-C ($P = 0.18$; Fig. 6). We compared NLS after SBD of patients who underwent PEBD to that of patients who underwent an SBD other than PEBD. NLS after SBD was comparable between the two groups (NLS at 10 years of age after SBD, 65% versus 56%, respectively; $P = 0.37$). Because sBAs decreased significantly after SBD and had been associated with long-term NLS in severe BSEP deficiency patients,⁽²⁸⁾ ROC analyses were performed for post-SBD sBA levels in relation to NLS after SBD. A post-SBD sBA level $<65 \mu\text{mol/L}$ tended to be associated with prolonged NLS after SBD ($P = 0.05$; AUC sBAs: 0.589; sensitivity 80%, specificity 61%; Fig. 7). A decrease of at least 76% (based on ROC) in sBAs was not associated with improved NLS after SBD ($P = 0.21$; AUC % change sBAs: 0.525; cut-off 76%: sensitivity 80%, specificity 44%). The proportion of patients achieving a post-SBD sBA level $<65 \mu\text{mol/L}$ was comparable between FIC1-A (45%), FIC1-B (50%), and FIC1-C (63%) ($P = 0.48$), as was the proportion of patients achieving a decrease in sBA levels of at least 76% after SBD in FIC1-A (22%), FIC1-B (50%), and FIC1-C (57%) ($P = 0.16$).

Discussion

This study aimed to define the natural history of FIC1 deficiency and assess the effect of the presence of PPTMs, sBA concentrations, and SBD on long-term outcome. NAPPED herewith presents the largest cohort of genetically defined, FIC1 deficiency patients to date. The present data indicate that less than half of patients with FIC1 deficiency are alive with their native liver by the time they reach adulthood. Surprisingly, the genotype of FIC1 deficiency patients, with respect to presence of PPTMs, did not seem to reliably predict the phenotype. sBA concentrations at baseline (i.e., $<194 \mu\text{mol/L}$ or $\geq 194 \mu\text{mol/L}$) and after SBD (i.e., $<65 \mu\text{mol/L}$ or $\geq 65 \mu\text{mol/L}$) may provide clinicians some prognostic information during counseling. For example, the proportion of patients who reach 15-year survival with native liver is 3-fold higher in patients with an sBA concentration at presentation below the threshold of $194 \mu\text{mol/L}$ than in those with sBA concentrations above the threshold. Additionally, SBD tended to be associated with improved NLS.

Our data indicate that most patients with FIC1 deficiency present to tertiary referral centers before the age of 1 year, but some patients presented as late as in their second decade of life. Variability in age at presentation was observed in patients with identical genotypes. It has been described that, even within the same family, a variable expression of disease may be present,^(30,33,34) which supports the notion that the phenotype of FIC1 deficiency is only to a limited amount determined by the genotype. However, this might partially reflect the referral pathway specialist centers, rather than only disease presentation. Upon their presentation at the tertiary referral center, patients had elevated levels of total sBAs, TSB, and aminotransferases. As reported, aminotransferases were less markedly elevated compared to severe BSEP deficiency⁽²⁸⁾ (up to an approximate 5-fold lower median), which has been described.⁽¹⁴⁾ Alfa-fetoprotein may also discriminate between severe BSEP deficiency and FIC1 deficiency,⁽¹³⁾ yet data unavailability precluded performing such an analysis.

We categorized patients according to the presence of PPTMs. Patients with a PFIC1 phenotype (i.e., continuous cholestasis and/or pruritus and continuous hepatocellular damage) were suggested to harbor truncating mutations more often than patients with a BRIC1 phenotype (i.e., episodic cholestasis and/or pruritus and transient hepatocellular damage).⁽³⁵⁾ Quantification of FIC1 transport functionality has been difficult, partly because the exact transport mechanism remains

elusive. Based on this limitation, we considered it reasonable to assume that the functionality of the FIC1 protein would be most severely affected in case of a PPTM. We then hypothesized that a gene dose effect would be present. However, we could not observe a significant impact of the number of PPTMs on phenotype in contrast to, for example, patients with severe BSEP deficiency.⁽²⁸⁾ The difference between FIC1 and BSEP deficiency in this respect could be related to the fact that mutations in *ATP8B1* only indirectly impact bile acid transport across the canalicular membrane in contrast to direct impact in BSEP deficiency. The current hypothesis holds that the transport activity of BSEP is affected secondary to alterations in the canalicular membrane composition, induced by FIC1 deficiency.⁽⁶⁾ Because the membrane composition is likely to be influenced by many more factors, genetic and environmental, the phenotype may be more influenced by variant compensatory influences. Support for this possibility can be derived from rather different phenotypic severities observed between individuals with identical FIC1 genotypes in the present study. The patients in our present study did not demonstrate clear phenotypic differences at baseline, nor were the genotype categories associated with NLS, biochemistry after SBD, or NLS after SBD. If anything, patients who would be expected to have a more severe genotype (i.e., FIC1-C) presented at a significantly younger age than patients with predicted milder genotypes (i.e., FIC1-A and FIC1-B). On the contrary, patients with an FIC1-C phenotype underwent SBD less often than FIC1-A and FIC1-B patients yet presented similar NLS. In addition, FIC1-C patients were most likely to achieve a post-SBD SBA concentration <194 µmol/L. The fact that patients with identical genetic profiles may present different phenotypes, even within the same family,^(30,34,35) again indicates that *ATP8B1* genotype might not be the main determinant in the natural history of FIC1 deficiency. This is further supported by data from our study (which includes some patients described in the referenced papers). Patients with the homozygous c.2932-3C>A mutation did not all express a BRIC phenotype; some already manifested a PFIC phenotype at presentation. Additionally, these patients underwent diversion at different ages (or did not undergo diversion at all). Notably, we excluded 1 patient with a homozygous c.2932-3C>A mutation due to the absence of a PFIC phenotype at last follow-up. The case may be, therefore, that variations as described here result from factors other than *ATP8B1* genotype, as yet unknown. For example, environmental exposures (e.g., drugs or nutrition), local management strategies, or other genetic factors (such as modifiers) may exert a more significant impact than we currently anticipate.

This study identified two relative large patient subgroups with homozygous c.923G>T; p.Gly308Val or c.1660G>A; p.Asp554Asn mutations. The first mutation is originally found in the Amish kindred, first published by Clayton et al., who termed the disease “Byler disease.”⁽³⁶⁾ Patients with homozygous p.Gly308Val mutations in the present study had mild disease in terms of NLS provided they had undergone SBD at young age. Their NLS was significantly higher than patients with homozygous p.Asp554Asn, but it is unclear to what extent the lower fraction undergoing SBD in the latter group contributed to the observed difference. The p.Asp554Asn was originally identified in the Inuit and has subsequently also been described in ethnically distinct individuals.^(30,37) Both the p.Gly308Val and the p.Asp554Asn mutations are missense mutations, and both have been associated with a PFIC phenotype. Our study could not demonstrate clear differences in the phenotype of these two groups with homozygous mutations.

Although the number of nonfunctional protein-type mutations could not reliably predict the phenotype of FIC1 deficiency, our data suggest that biochemistry at presentation in the tertiary center had prognostic value regarding the natural history of patients with FIC1 deficiency. An sBA level <194 $\mu\text{mol/L}$ was associated with long-term NLS after presentation. To our knowledge, this is the first study to provide a surrogate marker for long-term outcome in FIC1 deficiency. The fact that an sBA level <194 $\mu\text{mol/L}$ at baseline is associated with improved NLS may suggest that it seems beneficial for long-term NLS to interrupt the enterohepatic circulation (EHC) and alleviate patients of bile acid accumulation. Our results should be interpreted with some caution, however. First, the sBA concentrations had not been obtained in a standardized manner with respect to fasting or postprandial state. We cannot exclude that this has affected the results. Second, as stated above, the results on sBA concentrations did not reach the predefined cut-off of statistical significance ($P = 0.05$ rather than $P < 0.05$).

The relationship between low sBAs and beneficial long-term prognosis may be more complex than would be anticipated. SBD may protect the liver against systemic bile acid accumulation by interrupting the EHC. Our study demonstrates that SBD can successfully decrease sBAs, relatively shortly after the procedure. Moreover, SBD tended to be associated with NLS in the multivariate, time-dependent Cox regression model. Overall, an FIC1-B genotype was associated with lower NLS, but NLS was not significantly different between the three groups if determined either before or after 7 years of NLS in this model. We could not identify why this difference existed. It should

be noted that after 7 years of NLS, only 12 patients were still in the analysis. Although it is likely that these low numbers contributed (partly) to the observed trend toward lower NLS in FIC1-B patients, this outcome warrants further research. SBD seems to be associated with improved NLS in those patients who achieve a post-SBD sBA level $<65 \mu\text{mol/L}$. To characterize those patients who seemed to significantly benefit from SBD, we scrutinized patients with long-term NLS and low sBAs after SBD. We could not, however, identify factors, such as genotype, sex, or age at diversion, that were associated with the response to SBD. Also, at presentation, we could not identify differences in patient characteristics, biochemistry, or use of medication between patients who did and did not undergo SBD during follow-up (data not shown). Our study lacked data regarding pre-SBD fibrosis, which could have influenced post-SBD outcomes. Nevertheless, our data do support one of our main findings, which is that genotype, with respect to the presence of PPTMs, does not seem to reliably predict the phenotype of FIC1 deficiency. The fact that FIC1 is not directly involved in bile acid transport may be of importance. Indeed, the molecular mechanisms by which FIC1 contributes to cholestasis have still to be elucidated in more detail. Cholestasis might result from the indirect inhibition of other canalicular transporters such as BSEP, resulting from increased vulnerability to canalicular bile acids.^(6,11) Staining of these proteins does, however, seem to be unaffected in murine studies.^(26,28) To elucidate these mechanisms, further (fundamental) research is required to gain more insight into this difficult disease.

In the present cohort, we did not observe any incidence of HCC before transplantation or upon transplantation in explanted livers. Indeed, as far as we have found in the literature, there have been no reports of HCC in FIC1 deficiency patients, which is in contrast to the high prevalence of HCC in severe BSEP deficiency.^(28,38,39) If indeed mutations in *ATP8B1* impact bile acid transport indirectly (e.g., through BSEP), it is surprising that HCC does not develop in patients with FIC1 deficiency. Up until now, there is no proven explanation for this discrepancy between the two diseases. We speculate that the tumor-promoting pathways described in severe BSEP deficiency⁽⁴⁰⁾ are not induced in FIC1 deficiency. The zonal or subcellular accumulation of bile acids may differ between the two diseases, as well as the composition of the retained bile acids, which may lead to differences in the toxicity and/or carcinogenicity.

We realize that FIC1 deficiency extends beyond the liver, due to expression in tissues such as intestine, pancreas, lungs, and inner ear. Patients may present diarrhea, pancreatitis, or exocrine pancreatic insufficiency and sensorineural hearing loss.^(14,16-18,21) Currently, extrahepatic manifestations of FIC1 deficiency are not documented in our REDCap database, and therefore they could not be analyzed in the present paper. Some results in the present study should therefore be interpreted with caution because we cannot exclude the possibility that factors other than the hepatic phenotype have contributed to decisions regarding SBD or LT. Future research initiatives of NAPPED will focus on elucidating the extrahepatic features and their impact on the disease, both before and after LT. For example, therapy-resistant diarrhea may complicate the posttransplant disease course.⁽²⁷⁾

Despite its large size, our study was limited by missing data. For example, data regarding the indication for LT were lacking in 10 patients. However, we feel that the numbers are sufficient to provide novel insights into the disease. Because patients in the present study have been included from regions all over the globe, local treatment strategies may have interfered with outcomes. However, sensitivity analyses showed that neither the geographical region nor the center from which patients originated significantly impacted our main results. Finally, follow-up in this study stopped at the time of LT. Therefore, complications after LT, such as (aggravated) diarrhea, graft steatosis, and inflammation, have not been studied in this analysis.^(23,27,41,42)

In conclusion, our study shows that less than 50% of the patients with FIC1 deficiency reach adulthood with their native liver. The predicted genotypic severity with respect to PPTMs did not reliably predict the long-term phenotype. Biochemical parameters, such as sBA concentrations at presentation and after SBD, can predict long-term outcome and have potential to be used during counseling and treatment of patients. SBD tended to be associated with NLS. Our study further enhances the understanding of the difficult disease that FIC1 deficiency is, which allows for better care during childhood and adulthood, better prognostication of the disease, and better means to assess the effect of interruption of the EHC.

Acknowledgment: We thank Daan van Wessel for study concept and design, acquisition of data, analysis and interpretation of data, statistical analysis, drafting of the manuscript, and obtaining funding; Richard Thompson, Emmanuel Gonzales, Irena Jankowska, Benjamin L. Shneider, and Etienne Sokal for study concept and design, acquisition of data, and critical revision of the manuscript for important intellectual content; Tassos Grammatikopoulos, Agustina Kadaristiana, Anne Spraul, Piotr Czubkowski, Patryk Lipiński, Nathalie Rock, Mohammad Shagrani, Dieter Broering, Talal Algoufi, Nejat Mazhar, Emanuele Nicastrò, Deirdre Kelly, Gabriella Nebbia, Henrik Arnell, Björn Fischler, Jan Hulscher, Daniele Serranti, Cigdem Arıkan, Dominique Debray, Florence Lacaille, Cristina Goncalves, Loreto Hierro, Gema Muñoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Breclj, Antal Dezsöfi, Pier Luigi Calvo, Dorothee Krebs-Schmitt, Ekkehard Sturm, Wendy van der Woerd, Jian-She Wang, Liting Li, Özlem Durmaz, Nanda Kerkar, Marianne Hørby Jørgensen, Ryan Fischer, Carolina Jimenez-Rivera, Seema Alam, Mara Cananzi, Mathias Ruiz, Cristina Targa Ferreira, Felipe Ordonez, Heng Wang, Kyungmo Kim, Huey-Ling Chen, Elisa Carvalho, Alexandre Faber, Jesus Quintero Bernabeu, Estella M. Alonso, Ronald J. Sokol, Frederick J. Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Turmelle, Girish S. Rao, Simon Horslen, Binita Kamath, Maria Rogalidou, and Wikrom W. Karnsakul for acquisition of data and critical revision of the manuscript for important intellectual content; Emmanuel Jacquemin for critical revision of the manuscript for important intellectual content; Bettina Hansen for study concept and design, analysis and interpretation of data, statistical analysis, drafting of the manuscript, and obtaining funding; and Henkjan Verkade for acquisition of data, study concept and design, analysis and interpretation of data, drafting of the manuscript, and obtaining funding. We also thank the patients and their families for the important data; all contributing centers and investigators that are currently or will soon be participating in NAPPED; and all our individuals who provided care for the patients included in this study and/or have supported the present initiative.

REFERENCES

- 1) Elferink RO, Groen AK. Genetic defects in hepatobiliary transport. *Biochim Biophys Acta* 2002;1586:129-145.
- 2) Bull LN, Thompson RJ. Progressive familial intrahepatic cholestasis. *Clin Liver Dis* 2018;22:657-669.
- 3) **Noe J, Kullak-Ublick GA**, Jochum W, Stieger B, Kerb R, Haberl M, et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. *J Hepatol* 2005;43:536-543.
- 4) Bull LN, Van Eijk MJT, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. *Nat Genet* 1998;18:219-224.
- 5) Andersen JP, Vestergaard AL, Mikkelsen SA, Mogensen LS, Chalat M, Molday RS. P4-ATPases as phospholipid flippases: structure, function, and enigmas. *Front Physiol* 2016;7:275. doi: 10.3389/fphys.2016.00275.
- 6) Paulusma CC, de Waart DR, Kunne C, Mok KS, Elferink RP. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. *J Biol Chem* 2009;284:9947-9954.
- 7) Folmer DE, van der Mark VA, Ho-Mok KS, Oude Elferink RP, Paulusma CC. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. *HEPATOLOGY* 2009;50:1597-1605.
- 8) Cai SY, Gautam S, Nguyen T, Soroka CJ, Rahner C, Boyer JL. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. *Gastroenterology* 2009;136:1060-1069.
- 9) Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. *Gastroenterology* 2004;126:756-764.
- 10) **Frankenberg T, Miloh T**, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, et al. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. *HEPATOLOGY* 2008;48:1896-1905.
- 11) Demeilliers C, Jacquemin E, Barbu V, Mergey M, Paye F, Fouassier L, et al. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR

downregulation. HEPATOLOGY 2006;43:1125-1134.

12) Koh S, Takada T, Kukuu I, Suzuki H. FIC1-mediated stimulation of FXR activity is decreased with PFIC1 mutations in HepG2 cells. J Gastroenterol 2009;44:592-600.

13) Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. HEPATOLOGY 2010;51:1645-1655.

14) Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 2010;53:170-178.

15) Tygstrup N, Steig BA, Juijn JA, Bull LN, Houwen RH. Recurrent familial intrahepatic cholestasis in the Faeroe Islands: phenotypic heterogeneity but genetic homogeneity. HEPATOLOGY 1999;29:506-508.

16) **Stapelbroek JM, Peters TA**, van Beurden DH, Curfs JH, Joosten A, Beynon AJ, et al. ATP8B1 is essential for maintaining normal hearing. Proc Natl Acad Sci U S A 2009;106:9709-9714.

17) **Ray NB, Durairaj L**, Chen BB, McVerry BJ, Ryan AJ, Donahoe M, et al. Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat Med 2010;16:1120-1127.

18) Folvik G, Hilde O, Helge GO. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases. Scand J Gastroenterol 2012;47:482-488.

19) Nagasaka H, Yorifuji T, Kosugiyama K, Egawa H, Kawai M, Murayama K, et al. Resistance to parathyroid hormone in two patients with familial intrahepatic cholestasis: possible involvement of the ATP8B1 gene in calcium regulation via parathyroid hormone. J Pediatr Gastroenterol Nutr 2004;39:404-409.

20) **Verhulst PM, van der Velden LM**, Oorschot V, van Faassen EE, Klumperman J, Houwen RH, et al. A flippase-independent function of ATP8B1, the protein affected in familial intrahepatic cholestasis type 1, is required for apical protein expression and microvillus formation in polarized epithelial cells. HEPATOLOGY 2010;51:2049-2060.

21) Walkowiak J, Jankowska I, Pawlowska J, Bull L, Herzig KH, Socha J. Normal pancreatic secretion in children with progressive familial intrahepatic cholestasis type 1. Scand J Gastroenterol 2006;41:1480-1483.

- 22) Li L, Deheragoda M, Lu Y, Gong J, Wang J. Hypothyroidism associated with ATP8B1 deficiency. *J Pediatr* 2015;167:1334-1339.e1.
- 23) Bull LN, Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Dodge JL, et al. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. *Hepatol Commun* 2018;2:515-528.
- 24) Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. *Pediatr Transplant* 1999;3:219-224.
- 25) Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loret-de-Mola O, Nahmad M, Burnweit CA. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. *J Pediatr Surg* 1998;33:220-224.
- 26) Arnell H, Bergdahl S, Papadogiannakis N, Nemeth A, Fischler B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. *J Pediatr Surg* 2008;43:1312-1320.
- 27) Nicastro E, Stephenne X, Smets F, Fusaro F, de Magnee C, Reding R, et al. Recovery of graft steatosis and protein-losing enteropathy after biliary diversion in a PFIC 1 liver transplanted child. *Pediatr Transplant* 2012;16:E177-E182.
- 28) van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. *J Hepatol* 2020;73:84-93.
- 29) Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-381.
- 30) Klomp LW, Vargas JC, van Mil SW, Pawlikowska L, Strautnieks SS, van Eijk MJ, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. *HEPATOLOGY* 2004;40:27-38.
- 31) Takatsu H, Tanaka G, Segawa K, Suzuki J, Nagata S, Nakayama K, et al. Phospholipid flippase activities and substrate specificities of human type IV P-type ATPases localized to the plasma membrane. *J Biol Chem* 2014;289:33543-33556.
- 32) van der Woerd WL, Mulder J, Pagani F, Beuers U, Houwen RHJ, van de Graaf SFJ. Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. *HEPATOLOGY* 2015;61:1382-1391.

- 33) Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. *Arch Dis Child* 1996;75:223-227.
- 34) Bull LN, Juijn JA, Liao M, van Eijk MJ, Sinke RJ, Stricker NL, et al. Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. *Hum Genet* 1999;104:241-248.
- 35) van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, Houwen RH. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. *J Hepatol* 2002;36:439-443.
- 36) Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred. *Am J Dis Child* 1969;117:112-124.
- 37) Klomp LW, Bull LN, Knisely AS, van Der Doelen MA, Juijn JA, Berger R, et al. A missense mutation in FIC1 is associated with greenland familial cholestasis. *HEPATOLOGY* 2000;32:1337-1341.
- 38) Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. *HEPATOLOGY* 2006;44:478-486.
- 39) Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerova D, Rayner A, Dutton L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. *Gastroenterology* 2008;134:1203-1214.
- 40) Iannelli F, Collino A, Sinha S, Radaelli E, Nicoli P, D'Antiga L, et al. Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency. *Nat Commun* 2014;5:3850. doi: 10.1038/ncomms4850.
- 41) Miyagawa-Hayashino A, Egawa H, Yorifuji T, Hasegawa M, Haga H, Tsuruyama T, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. *Liver Transpl* 2009;15:610-618.
- 42) Aydogdu S, Cakir M, Arian C, Tumgor G, Yuksekkaya HA, Yilmaz F, et al. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth. *Pediatr Transplant* 2007;11:634-640.
- Author names in bold designate shared co-first authorship.

Figure Legends

FIG. 1. Flowchart of patient inclusion from the NAPPED database and subsequent categorization based on genotype. *: either only one mutation in ATP8B1, ATP8B1 mutations of no (known) clinical consequence, mutations in ABCB11/TJP2 or participation in investigational drug trials.

#Episodic cholestasis and/or pruritus and transient hepatocellular damage. †: splice site, frameshift due to deletion or insertion, nonsense, duplication. Abbreviations: BRIC, benign recurrent intrahepatic cholestasis; FIC1, familial intrahepatic cholestasis type 1; FIC1-A, no PPTM; FIC1-B, 1 PPTM; FIC1-C, 2 PPTMs; GGT, gamma-glutamyltranspeptidase; PPTM, predicted protein truncating mutation.

FIG. 2. Proportion of all patients alive with native liver with a surgical diversion over time (A) and proportion of patients alive with native liver (B) in all patients.

FIG. 3. Proportion of patients with a surgical diversion (A) and proportion of patients alive with native liver (B) in patients without predicted protein type mutations (PPTMs, FIC1-A), with one PPTM (FIC1-B) or two PPTMs (FIC1-C).

FIG. 4. Pre- and post-SBD biochemistry. sBAs (A), TSB (B), ALT (C) and AST (D) in FIC1-A (filled circles), FIC1-B (open circles) and FIC1-C (triangles) patients for whom paired data was available. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; sBAs, serum bile acids; SBD, surgical biliary diversion; TSB, total serum bilirubin.

FIG. 5. Observed native liver survival (x axis) in all FIC1 patients, that underwent surgical biliary diversion (SBD, n=62) or not (n=68). The clock-reset approach allows visualization of native liver survival up to SBD (solid line, all patients) and after SBD (dotted line, only patients that underwent SBD). The estimated hazard ratio is achieved by Cox-regression with SBD as a time-dependent risk-factor, adjusted for genotype, sex and birth year. Abbreviations: CI, confidence interval; HR, hazard ratio.

FIG. 6. Native liver survival after surgical biliary diversion in patients with a FIC1-A (no truncating mutations), a FIC1-B (one truncating mutation) or a FIC1-C (two truncating mutations) genotype.

FIG. 7. Native liver survival after surgical biliary diversion in patients with a serum bile acid concentration of $<65\mu\text{mol/L}$ vs. $\geq 65\mu\text{mol/L}$.

TABLE 1. Characteristics and Biochemistry for all Patients According to FIC1 Genotype

Parameter	All Patients (n = 130)	Category Mutations			P Value*
		FIC1-A (n = 67; no PPTM)	FIC1-B (n = 29; 1 PPTM)	FIC1-C (n = 34; 2 PPTMs)	
Year of birth, years	2007 (1999-2012)	2009 (2004-2014)	2006 (1995-2011)	2006 (1996-2011)	0.04
Available n (%)	130 (100)	67 (100)	29 (100)	34 (100)	
Year of birth time frame	1981-2019	1981-2019	1982-2017	1984-2017	-
Males, n (%)	71 (55)	33 (49)	17 (59)	21 (62)	0.09
Available n (%)	130 (100)	67 (100)	29 (100)	34 (100)	
Age at first visit, years	0.6 (0.3-2.2)	0.8 (0.4-3.0)	0.9 (0.4-2.7)	0.4 (0.2-0.7)	0.004
Available n (%)	130 (100)	67 (100)	29 (100)	34 (100)	
Year of first visit, years	2010 (2006-2014)	2011 (2008-2014)	2010 (1999-2013)	2007 (1996-2013)	0.01
Available n (%)	130 (100)	67 (100)	29 (100)	34 (100)	
Year of first visit time frame	1982-2019	1982-2019	1989-2018	1985-2017	-
Prior to presentation ever treated with:					
UDCA, n (%)	41/103 (40)	23/46 (50)	10/26 (39)	8/31 (26)	0.01
Rifampicin, n (%)	16/103 (16)	6/46 (9)	3/26 (12)	7/31 (23)	
Phenobarbital, n (%)	10/103 (10)	2/46 (3)	4/26 (15)	4/31 (13)	0.28
Cholestyramine, n (%)	12/103 (12)	5/46 (8)	2/26 (8)	5/31 (16)	0.74
Antihistamines, n (%)	9/103 (9)	5/46 (8)	2/26 (8)	2/31 (7)	0.35
Laboratory data at presentation					
sBAs, $\mu\text{mol/L}$	179 (122-220)	202 (138-223)	177 (129-211)	153 (117-200)	0.43
Available n (%)	69 (53)	32 (48)	14 (48)	23 (68)	
TSB, $\mu\text{mol/L}$	129 (64-220)	113 (61-193)	212 (123-373)	125 (65-173)	0.02
Available n (%)	103 (79)	46 (69)	24 (83)	33 (97)	
ALT, IU/L	48 (31-82)	55 (30-86)	41 (31-67)	49 (31-73)	0.67
Available n (%)	102 (78)	45 (67)	23 (79)	34 (100)	
AST, IU/L	66 (50-86)	64 (48-84)	67 (54-107)	69 (51-86)	0.64
Available n (%)	89 (68)	40 (60)	21 (72)	28 (82)	
GGT, IU/L	23 (17-35)	22 (15-35)	37 (21-41)	23 (15-31)	0.26
Available n (%)	90 (69)	37 (55)	24 (79)	30 (88)	
PLT, $10^9/\text{L}$	461 (313-569)	365 (241-538)	399 (288-484)	530 (394-625)	0.02
	57 (44)	24 (36)	14 (48)	19 (56)	


Available n (%)					
-----------------	--	--	--	--	--

Data are presented as medians and IQRs.

*Mantel-Haenszel test for trend or Kruskal-Wallis tests, as appropriate, to test differences between FIC1-A, FIC1-B, and FIC1-C.


‘-’ indicates that no statistical test was performed on this parameter.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIC1, familial intrahepatic cholestasis type 1; GGT, gamma-glutamyltranspeptidase; IQRs, interquartile ranges; PLT, platelet count; PPTM, predicted protein truncating mutation; sBAs, serum bile acids; TSB, total serum bilirubin; UDCA, ursodeoxycholic acid.




A

% of patients with surgical diversion




B

% of patients alive with native liver




hep_31787_f2.eps

A







# at risk	FIC1-A	67	8	4	3	1
	FIC1-B	29	8	3	3	2
	FIC1-C	34	14	6	3	3

B




# at risk	FIC1-A	67	26	14	8	6
	FIC1-B	29	16	6	4	4
	FIC1-C	34	18	10	7	6

hep_31787_f3.eps




hep_31787_f4.eps




hep_31787_f5.eps

% of patients alive with native liver



# at risk	FIC1-A	36	17	9	4
	FIC1-B	12	7	1	0
	FIC1-C	14	9	5	3

hep_31787_f6.eps



hep_31787_f7.eps